Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech disclosures can feel like a second language—especially when GRAIL’s 10-K spells out hundreds of pages of clinical trial statistics, cash-burn tables, and regulatory risk factors tied to its Galleri multi-cancer early detection test. Finding the pivotal trial read-outs or decoding executive stock moves before major data releases shouldn’t require a medical degree.
Stock Titan’s platform turns that challenge into a two-minute task. Our AI-powered summaries convert dense narratives into plain English, so understanding GRAIL SEC documents with AI is as direct as reading a headline. Receive real-time alerts the moment a GRAIL Form 4 insider transactions real-time notice hits EDGAR, review a distilled GRAIL quarterly earnings report 10-Q filing, or open a GRAIL 8-K material events explained brief that pinpoints new clinical milestones.
Use the filings that matter most:
- GRAIL annual report 10-K simplified – track R&D outlays, patent positions, and Galleri commercialization strategy.
- 10-Q trends – rapid GRAIL earnings report filing analysis for cash-runway checks.
- GRAIL insider trading Form 4 transactions – uncover buying or selling before clinical data drops.
- GRAIL proxy statement executive compensation – see how trial success metrics drive pay packages.
Whether you’re monitoring GRAIL executive stock transactions Form 4 or verifying a new partnership disclosed in an 8-K, our comprehensive, continuously updated library ensures GRAIL SEC filings explained simply. Skip the jargon, focus on the insight, and make faster, better-informed decisions about this precision-oncology pioneer.
CRCM and affiliated entities reported ownership of common stock of Grail, Inc. Combined filings show CRCM LP and related funds/vehicles collectively report beneficial ownership of 1,800,651 shares, representing 5% of the outstanding common stock based on a 36,047,799 share denominator. Individual CRCM vehicles report holdings ranging from 206,666 to 937,153 shares; the largest single reported holder among the group is CRCM G SPV, LP with 937,153 shares (2.6%). The filings state the shares are not held to change or influence control and include standard disclaimers of beneficial ownership by the investment manager and general partners. The reporting date for the required event is
Joshua J. Ofman, President of GRAIL, Inc. (GRAL), reported a sale of 9,692 shares of common stock on 10/02/2025 at a reported price of $64.0025 per share. After the transaction he beneficially owns 478,182 shares. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, and the Form 4 was signed by an attorney-in-fact on 10/03/2025. The report is a routine Section 16 disclosure showing an officer-initiated disposition under an established trading plan.
GRAIL, Inc. (GRAL) filed a Form 144 reporting a proposed sale of 89,237 shares of common stock with an aggregate market value of $5,848,592.98, based on an approximate sale date of 10/06/2025 on NASDAQ. The filing shows the securities were originally acquired on 10/03/2024 upon vesting of restricted stock units under the issuer's equity incentive plans; the acquisition amount reported is 152,810 shares and the stated nature of payment is services rendered with a payment date of 10/03/2025. The filing also discloses two recent sales by Joshua J. Ofman: 4,202 shares sold on 08/19/2025 for $134,548.04 and 9,692 shares sold on 10/02/2025 for $601,485.52. Certain filer identification fields (CIK/CCC and filer contact name) and issuer address details are not provided in the visible content.
GRAIL, Inc. filed a Form 144 disclosing a proposed sale of 9,692 common shares, acquired as restricted stock units on 04/30/2025, with an aggregate market value of $601,485.52. The filing identifies the broker as Morgan Stanley Smith Barney LLC and lists an approximate sale date of 10/02/2025 on NASDAQ. The filing also reports a recent sale by the same person of 4,202 shares on 08/19/2025 for gross proceeds of $134,548.04. The issuer's shares outstanding are listed as 36,047,799. The notice states the seller represents they possess no undisclosed material adverse information and includes the standard Rule 10b5-1 and misstatement warnings.
Joshua J. Ofman, identified as an officer (President) of GRAIL, Inc. (ticker GRAL), reported a sale of common stock on 08/19/2025. The Form 4 shows a transaction code S for the sale of 4,202 shares at a broker-calculated weighted average price of $32.02. After the sale, Ofman beneficially owned 487,874 shares on a direct basis. The filer notes the shares were sold as part of a block trade executed in multiple transactions and offers to provide detailed per-trade pricing on request. The form was signed by an attorney-in-fact on 08/20/2025.
Aaron Freidin, Chief Financial Officer and Director of GRAIL, Inc. (GRAL), reported a sale of 877 shares of GRAIL common stock on 08/19/2025 at a weighted-average price of $32.02 per share. After the reported transactions, he beneficially owns 285,143 shares, held directly. The filing states the sale was executed as a block trade in multiple transactions and that the broker-calculated price is a weighted average; the reporter offers to provide detailed per-trade pricing on request. No derivative transactions were reported.
Form 144 notice for GRAIL, Inc. (GRAL) states that an individual plans to sell 4,511 shares of the issuer's common stock on the NASDAQ with an aggregate market value of $147,964.08, against 36,047,799 shares outstanding. The securities were acquired on 06/28/2024 when 8,076 shares vested from restricted stock units issued by the company; payment was recorded as services rendered. The filer discloses two recent sales by the same person in the past three months: 9,692 shares sold on 06/12/2025 for $410,019.09 and 6,992 shares sold on 06/30/2025 for $503,984. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
GRAIL, Inc. Form 144 discloses a proposed sale under Rule 144 of 952 shares of common stock by the named person, with an aggregate market value of $30,873.36, and an approximate sale date of 08/21/2025 on the NASDAQ. The shares were acquired upon vesting of restricted stock units on 06/28/2024 and were granted as compensation for services. The filing also reports a prior sale by Aaron Freidin of 8,000 shares on 07/15/2025 generating gross proceeds of $311,440. The filer affirms no undisclosed material adverse information is known.
This Schedule 13G/A reports that PRIMECAP MANAGEMENT CO/CA beneficially owns 2,057,089 shares of GRAIL common stock (class reported as COM), representing 5.72% of the outstanding class. The filing discloses sole voting power over 2,027,466 shares and sole dispositive power over 2,057,089 shares.
The statement affirms the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Items identifying group members, subsidiaries and related classifications are marked not applicable, and the filing includes the certification required under Item 10 attesting to the accuracy of the disclosure.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
